FDA Expands Aethlon Hemopurifier IDE To Address Ebola
This article was originally published in The Gray Sheet
The agency approved an expanded clinical trial allowing Aethlon to test an Ebola treatment protocol at 10 U.S. sites; requires the company to gain institutional review board approval from each institution and the trials can only enroll up to 20 patients.
You may also be interested in...
FDA grants its seventh Ebola diagnostic EUA, this time to Roche, as global health officials continue efforts to try to contain the outbreak of the deadly disease in West Africa.
The World Health Organization has initiated a rapid review process and is providing early test validation materials to encourage more manufacturers to quickly develop rapid, point-of-care Ebola tests. Meanwhile, Aethlon Medical is providing its bio-filtration device to treat blood of Ebola patients.
The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.